COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic completes enrollment for Phase 3 ENSURE trials in Relapsing MS and presents positive Phase 2 CALLIPER trial data in Progressive MS, showcasing vidofludimus calcium's potential. Top-line data in 2026 -
-
-
-
-
-
